Comparison of effects of empagliflozin and linagliptin on renal function and glycaemic control: a double-blind, randomized clinical trial

HIGHLIGHTS

• who: Mohammad Amin Mohammad zadeh Gharabaghi from the We ran a randomized, double-blind, parallel trial (Iranian Registry of Clinical Trials identifier: IRCT, ) to compare the effects of Emplagiflozin , mg once daily and Linagliptin , mg once daily on albuminuria, fasting blood sugar (FBS), HbA1c, and eGFR in patients with type , DMAll patients were informed in detail about the study, and verbal and written informed consent were obtained. The study design entirely was approved by the Human Ethics Committee of the Arak University of Medical Sciences (ethics code:, .127.REC.ARAKMU.IR). Trial population have published the research . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.